DISCUSSION
Dr John Stokes (Chairman) said that when Dr Peters listed the antigens for the immune-complex renal diseases he separated out the staphylococci in infective endocarditis from other organisms which were much more common. Was one group more important than the other? Dr Peters said that a variety of organisms, including Staphylococcus albius, had been incriminated, and they had recently studied a patient with glomerulonephritis associated with rickettsial endocarditis. The point was that these patients had the scene set for chronic immune-complex disease. In the early literature on bacterial endocarditis in the preantibiotic era patients were described as in the bacteriafree stage of bacterial endocarditis, in that their blood culture was persistently negative. It was just this group that died of renal failure. It was not too difficult to explain that occurrence: they had long-standing infection and mounted a good antibody response. This was sufficient to prevent the organism being grown in the bloodstream but not to stop it multiplying in the heart valve and releasing antigens leading to chronic immune-complex disease.
However he had been rather simplistic because there were many difficulties. There was no doubt that after streptococcal infections a few patients developed chronic glomerular disease leading to renal failure. It was difficult to accept that these patients had persistent circulating immune complexes due to chronic streptococcal infection. One had to fall back on the idea that the initial damage in the kidneys somehow caused self-perpetuating renal damage. He speculated that one possible source of such a mechanism might be in the complement sequence. It was known that the properdin system for activating C3 required C3 itself, so that activation of C3 could activate a positive feedback cycle, resulting in further C3 breakdown. This process might then continue long after the primary allergic stimulus had ceased. Professor Ziff said that for 15 years they had a patient at their clinic who had systemic lupus erythematosus (SLE) and partial lipodystrophy. When a paper dealing with partial lipodystrophy appeared (Alper C A et al. 1973, New England Journal ofMedicine 288, 601) they reexamined their patient. Over many years she had a C3 level consistently around 20-25 mg/ 100 ml, far too low to be due to SLE. She had C3 splitting activity in her serum. Dr Peters asked Professor Ziff what the evidence was that his patient had SLE. Professor Ziff replied that they thought she had had it for 15 years. The basis for this opinion was that she had polyarthritis, attacks of pleurisy, occasional positive LE cell and antinuclear tests; they were rarer than one would expect but they were positive from time to time.
Dr H J Goldsmith (Liverpool) said that when nephrologists discussed glomerulonephritis they tended to observe a conspiracy of silence about the tubular and interstitial changes which were quite often disproportionately severe in this disease. Did Di Peters think these changes were entirely ischemic in origin, might they be immunological or was there any other explanation?
Dr Peters agreed that there seemed to be a conspiracy of silence on this area. In experimental animals it was possible to induce antitubular basement membrane antibody by immunization with urinary antigen or by immunization with renal extracts. These animals had linear deposits of antibody on the tubular basement membrane. The same appearances had been described in two patients, one from Dr McCluskey in Boston and one from Dr Liliane Morel-Maroger in Paris, who had tubular staining of antibody along the basement membrane.
The second group of disorders where there appeared to be reasonable grounds for thinking that allergic events were taking place were associated with those disorders of which Professor Margaret Turner-Warwick (p 541) had spoken, namely in hepatic disease and fibrosing alveolitis, where there were tubular abnormalities, often of a Fanconi syndrome type. Patients with such diseases had a wide range of non-organ-specific antibodies and also, interestingly, had abnormalities of leukocyte migration against renal antigens. It seemed possible that in these patients who, on renal biopsy, had extensive infiltrates in the mononuclear cells and tubular dilatation, cellmediated allergic reactions were responsible. For the rest he did not know; he suspected that many changes were ischoemic in origin, but it was possible that they were not. Professor J V Dacie asked if Dr Peters would comment on the absence from his list of rheumatoid complexes. Dr Peters said that the list was not intended to be comprehensive. Perhaps it was worth saying that circulating cryoglobulins seemed to be a feature of many diseases believed to be due to immune complexes. It was of great interest that for the first time for several years circulating cryoglobulins were no longer detectable in the patient with self-induced glomerulonephritis.
Blood by Professor
A substantial amount of a hmmatologist's laboratory work is immunological. Immunological techniques are thus used in blood transfusion work to identify blood group antigens and the corresponding alloantibodies and in carrying out cross-matching tests; and the same or similar techniques are employed in the investigation of hemolytic disease of the newborn and in the demonstration and identification of autoantibodies in the autoimmune hemolytic anmmias. 'Idiopathic' thrombocytopenic purpura (ITP) is, too, a disorder in which immunological processes are probably involved.
In the group of paraproteinmmias, of which myelomatosis is the most important disorder, the use of immunological techniques to demonstrate abnormal proteins is an essential step in their investigation. Immunological techniques are also used in the investigation of certain haemorrhagic disorders: for instance, in the identification of abnormal types of clotting factors and in the demonstration of antibodies (inhibitors) acting against clotting factors.
The megaloblastic anamias are another group of disorders in the investigation of which immunological techniques are utilized: for instance, in the identification of antibodies against gastric parietal cells and intrinsic factor and in radioimmune assay of vitamin B12. Then there is paroxysmal nocturnal haemoglobinuria. This remarkable disorder depends upon the red cell acquiring a greatly increased sensitivity to lysis by complement. Ham's test and the sucrose lysis test and other newer laboratory tests are all dependent on, or are designed to demonstrate, the increased complement sensitivity.
Blood cells may be involved in immune hypersensitivity reactions to drugs. This group of cytopenias is rare, but the disorders are important because of their potential severity. Thus haemolytic anemia, which may be very severe, has occurred in certain individuals as a consequence of their forming antibodies against drugs such as stibophen (Fouadin), quinidine, quinine, phenacetin and PAS, and acute thrombocytopenic purpura has followed the production of antibodies against apronal (Sedormid), quinidine and quinine and a few other drugs; similarly, acute agranulocytosis has followed the taking of amidopyrine and some sulphonamides and antithyroid drugs. The demonstration of the antidrug antibodies in serum is usually easy in the hemolytic aneemias and thrombocytopenias but much more difficult in the agranulocytoses.
The above disorders are certainly of common interest to immunologists, hematologists and general physicians. I shall now concentrate in the rest of this paper on one group only, namely, the autoimmune hTemolytic anemias (AIHA). They are particularly satisfying disorders from the point of view of demonstrating the autoantibodies and of observing the effects of treatment, as blood is the most easy of all tissue to biopsyby venepunctureand to study quantitatively by cell counts, &c. The AIHAs are important disorders, too, for their various clinical associations provide clues to the etiology of autoimmune diseases in general. Thus the development of AIHA in lymphomas, in association with other manifestations of autoimmune disease, as in SLE, and its occurrence following infections and omethyldopa therapy are of particular interest.
These associations underline the widely acknowledged interrelationships between malignant lymphomas, aberrant immune processes, infections and drugs and autoimmune disease.
The physician's interest in AIHA rightly extends beyond etiology and pathogenesis: it is also a practical one. He wants to know how to diagnose AIHA, how to treat his patient and what the prognosis is. AIHA is diagnosed by demonstrating that the patient is forming antibodies capable of interacting with antigens on the red cell surface. This is best done by the direct Coombs or antiglobulin test which detects antibody globulins and/or complement adsorbed to the red cell; and it is possible, using specific antisera, to determine which type of immunoglobulin is involved -IgG, IgA or IgM. Autoantibodies may similarly be detectable in the patient's serum, and if the patient is suffering from increased hmmolysis and the direct antiglobulin test is positive, AIHA can be diagnosed with confidence. The use of a panel of red cells of known genotype enables the specificity of the antibody to be determined in many cases, and this can be of considerable importance in relation to blood transfusion should this be necessary.
As always, the occasional case may present difficulties in diagnosis. Thus patients receiving long-continued high-dose penicillin therapy may develop antibodies to penicillin derivatives and give positive direct antiglobulin tests, and develop hemolytic anmmia, closely stimulating AIHA.
And there are other possible causes of positive antiglobulin tests not associated with AIHA. However, as in most of these cases there is no evidence of increased hmmolysis, they are seldom a serious cause of confusion. It must also be added that a positive antiglobulin test caused by a genuine autoantibody may not be associated with clinical or laboratory evidence of hamolytic anemia. In fact the great majority of patients being treated with cx-methyldopa in whom the direct antiglobulin test is positive do not suffer from increased haemolysis. Insufficient antibody is formed to bring this about.
Serologically and immunochemically, cases of AIHA can be broadly divided into several groups: the warm type, in which the antibodies act readily at body temperature, and the cold type in which the antibodies, cold agglutinins, do not act at 37°C, but act progressively more strongly as the temperature is reduced from approximately 30°C to 0°C. Cases of paroxysmal cold hamoglobinuria due to the rare Donath-Landsteiner cold antibody comprise a rare third type. Clinically, too, the patient's signs and symptoms vary. Thus haemoglobinuria and Raynaud's phenomena are characteristic features of the cold type. From all points of view, particularly in relation to therapy and prognosis, it is important to know from which type of disorder the patient is suffering. Once AIHA has been diagnosed, the next question to decide is whether the patient is suffering from an underlying or associated disease, secondary AIHA, or whether the disorder is of unknown origin, the so-called 'idiopathic' type (Table 1 ). Treatment and prognosis may well be influenced by the nature of the associated disease. Thus a patient may die of his lymphoma despite his hmmolytic anamia being brought under control. Likewise, the most effective therapy in a patient whose haemolytic anemia has been brought about by a-methyldopa would be to change to another antihypertensive drug, and in the rare instances in which AIHA complicates an ovarian teratoma, the teratoma must be removed if the h;emolysis is to subside. In general, however, the treatment of AIHA, whether idiopathic or secondary, is the same, namely, protection of the patient from the worst effects of increased hmmolysis using the minimum of therapy, in the hope that autoantibody formation will eventually subside.
Treatment can be considered under four headings: blood transfusion to buy time, corticosteroid therapy to repress phagocytosis, splenectomy to remove an organ causing red cell destruction and the formation of autoantibodies, and immunosuppressive therapy to diminish autoantibody formation. Each treatment has its limitations and dangers. None, with the theoretical exception of immunosuppressive therapy, can be expected to effect a cure. ' Blood transfusion is essentially palliative but it may provide time for more effective therapy, e.g., corticosteroid therapy, to take effect. Almost always, antibodies acting on the patient's red cells act on antigens present on normal red cells. In warm-type AIHA it is thus difficult and often impossible to obtain blood which is compatible in a pretransfusion cross-matching test. Sometimes clearly incompatible blood has to be transfused. However, the transfused red cells are not likely to be more incompatible than are the patient's red cells, and in practice most patients tolerate transfusion without major upset. Of course any rise in htemoglobin is likely to be short-lived, but a temporary respite may be of value, even lifesaving. Patients with cold-type AIHA, too, can usually be safely transfused if the blood is given warmed to near body temperature and transfused slowly. In practice, it is, however, unusual for such a patient to need transfusion.
Corticosteroids, e.g., prednisolone, remain the drugs of choice for a patient with warm type AIHA. Oral prednisolone 60-100 mg daily should be given initially, depending on the severity of hemolysis. This high dosage should be maintained until haemolysis subsides and the patient's htmoglobin rises. In most patients this takes place within 5-10 days and at least 80 % of patients respond. As soon as hemolysis subsides, the dose of prednisolone can be reduced, the aim being to allow the patient to maintain a hvmoglobin level of at least 10 g/100 ml on as small a dose of corticosteroid as possible. At least half of the patients who respond initially will relapse on a low (i.e., 10-15 mg) daily dose of prednisolone. In these the dose must be increased in an attempt to achieve stabilization of hwmoglobin, if possible on a dosage not exceeding 25 mg daily. It is usually a question of trial and error and careful modification of dosage over a long period of time. There has been debate as to whether ACTH has an advantage over oral prednisolone in seriously ill patients. The question has not been satisfactorily settled, but it has been our practice in seriously ill patients not apparently responding satisfactorily to prednisolone to give in addition 60-80 units of ACTH intramuscularly daily. Several such patients have responded; perhaps they would have done so if we had simply increased the dosage of prednisolone. Prednisolone has been mentioned as the corticosteroid used in routine therapy; there seems to be no evidence that any other steroid is superior to it in equivalent dosage.
In cold-type AIHA steroids should seldom be given. The patients are often not very antemic; they are usually elderly and because their disease is likelyin idiopathic cases at leastto be long continued, it is wiser, if any treatment at all seems indicated, to use a drug such as chlorambucil rather than corticosteroids. On the other hand, in the acute transient cold-type AIHA which occasionally follows mycoplasma pneumonia a short course of prednisolone may be of considerable benefit and can be safely given. Splenectomy is of greatest value in warm-type AIHA in which the antibody is of the common IgG incomplete type. Probably some benefit follows splenectomy irrespective of the type of antibody. Splenectomy cannot, however, be expected to cure the patient, for the spleen is only one site of red cell destruction and of autoantibody formation. Its removal may nevertheless reduce the rate of hvmolysis sufficiently for virtual clinical cure; or it may allow a patient to maintain a satisfactory hemoglobin level on a dose of corticosteroids substantially less than was needed before.
It has been our practice to recommend splenectomy for patients with warm-type AIHA when hmmolysis cannot, after initial high dose therapy, be controlled by relatively small daily doses of prednisolone (e.g., 20 mg or less), or if on a small daily dose serious complications of therapy are threatened or have developed. The results of splenectomy have been difficult to assess, for the operation has generally been carried out on the more rather than on the less seriously ill patients.
A review published in 1956 of the results of splenectomy in 21 patients with the idiopathic warm type of disease showed that 4 achieved clinical cure and 8 some benefit, while the results were classified as poor or doubtful in 9 (Chertkow & Dacie 1956 ). All these patients had either not received steroids or had received doses which by presentday standards would be considered far too small. The experience of other authors has been much the same, namely, that between onehalf and two-thirds of patients submitted to splenectomy derive some benefit. Splenectomy has seldom been carried out in cold-type AIHA where the spleen is known to be of relatively less importance in hrmolysis, and it is difficult to make a case for splenectomy before a trial of chemotherapy. Chemotherapy: Drugs such as azathioprine (Imuran) or chlorambucil might be expected to be useful in the treatment of AIHA because of their known immunosuppressive action. In practice they have proved to be rather disappointing. Some patients undoubtedly derive benefit, but other appear refractory or become refractory after responding favourably at first (Tables 2 and 3 ). The drugs, too, have the theoretical disadvantage of being marrow depressants, and also of causing a general depression of immunoglobulin formation with a consequent increased susceptibility to infection. In practice neither effect seems to be very important, although a marked depression in serum immunoglobulins has been observed in some of our patients on long-term azathioprine therapy. It is a matter of current debate whether long-term immunosuppressive therapy increases a patient's chances of developing a malignant tumour. This seems to be so in patients with a renal transplant receiving azathioprine; but whether the risk is as great in AIHA has yet to be determined. Two of our patients have in fact developed lymphoreticular neoplasms following immunosuppressive therapy, but the role of the drug is uncertainbecause such occurrences are not too uncommon in patients with AIHA who'have received no such treatment.
It is also a matter for debate whether a patient with warm-type AIHA refractory to corticosteroids should be given a trial of an immunosuppressive drug prior to splenectomy or vice versa. Up to now we have recommended splenectomy first on the grounds that the results of immunosuppressive therapy are unpredictable and often disappointing, and because of the possible risks of therapy. We admit, however, that splenectomy is not without risk and that the results are often disappointing.
It is difficult to give figures for prognosis in AIHA. Few physicians have seen many patients and those few have not seen an unselected series. In observations made between 1948 and 1961 (Dacie 1962 ) the mortality in 50 patients with warm-type AIHA was as high as 46 %, but many patients had been referred because they were refractory to the then available treatment. Over the last ten years the figures that Dr S Worliedge and I have collected have been far better. The mortality in 105 patients has been 10.5%; 20% achieved clinical cure, the illness continuing in the remainder. It is interesting that the proportion achieving cure, 20 %, was the same as in the earlier series in which the mortality was much greater, suggesting that improved treatment, although clearly a factor in diminishing mortality, has had little effect on the cure rate.
A speaker wished to ask a practical question about methyldopa: for a patient who was well stabilized on the drug, who had a positive Coombs test but nothing elseand Professor Dacie said that only 1 % or less developed anything more than that -should one in fact change? Were there any long-term ill effects that one should determine to avoid? Professor Dacie thought one should continue methyldopa treatment, but follow the patient rather more carefully than the others. Once the Coombs test was discovered to be positive he thought it should be repeated from time to time. Patients tended to produce a level amount of antibody. Most of those who had developed positive antiglobulin tests, if kept on the same dosage, gave the same kind of reactions. Thus he would continue the treatment, but would watch the patient more closely than otherwise.
The Immunology of Liver Disorders by Geoffrey Walker MD MRCP (St Mary's Hospital, London W2) There has been a very great increase during the last fifteen years in our knowledge of the interrelationships between liver disorders and disturbed immunological processes. It is now recognized that three chronic liver syndromes are associated regularly with autoantibodies in the serum: primary biliary cirrhosis (PBC), active chronic hepatitis (ACH) and cryptogenic cirrhosis. Whether these disorders can be considered as belonging to the group of idiopathic autoimmune diseases is, however, still unresolved although hepatic cirrhosis was one of the first conditions investigated immunologically. Moreover, ideas about hepatitis are changing rapidly since the discovery of the hepatitis-associated (Australia) antigen (HBAg), while the use of polytransfused sera has revealed antigenic materials possibly connected with other viruses which may also be implicated in the pathogenesis of chronic (or acute) liver inflammation.
This review sets out to evaluate immunological phenomena, in particular autoimmune phenomena, as they occur in inflammatory liver disorders, and to discuss their pathogenetic and diagnostic implications. Genetic aspects of the immune processes and their relationships to viruses, drugs and other external factors are also considered. No attempt is made to discuss transplantation of the liver in man or the use of immunological tests for fetal antigens in the serum of patients with primary malignant disease of the liver, although the practical importance of such tests is fully recognized.
Hyperglobulina?mia Hyperglobulinemia in various liver diseases is well recognized but its pathogenesis is uncertain. Synthesis of several different classes of immunoglobulins is increased, but whether this is due to excessive antigenic stimulus, to generalized hyperactivity of the lymphoreticular system, or to both, is not known. One possible stimulus to antibody formation is breakdown of hepatic tissue. Following experimental liver injury, immunoglobulin synthesis is increased and these immunoglobulins consist in part of autoantibodies. The latter, however, are poorly defined and react with a variety of tissues. Alternatively, the stimulus could arise from identified or unidentified infective agents responsible for the liver disease; or, again, the relationship to the liver condition itself may be indirect.
In acute inflammation, as in virus hepatitis, a modest increase in gamma globulin occurs 7-14 days after onset, but this usually returns to normal within a few weeks and persistence of high levels may indicate transition to chronic liver disease and the development of cirrhosis. In this condition, serum protein electrophoresis may show /-y fusion due to increase in the faster globulins (yl) whereas a narrow distinct gamma peak is characteristic of active chronic hepatitis and consists essentially of slower Y2 globulins (Hobbs 1966). Rarely, a monoclonal picture may be seen.
Serum Immunoglobulin Changes
A generalized rise of one or more serum immunoglobulins is a feature of many acute and chronic liver diseases (Feizi 1968 , Hobbs 1970 . Certain chronic disorders are associated with typical patterns of immunoglobulin elevation. Thus the markedly elevated IgG levels in ACH led to the alternative name of 'hypergammaglobulinemic hepatitis', while IgM elevation is characteristic of primary biliary disease where it may be of help in differentiation from other types of cholestasis. However, as individual cases frequently deviate from the general trend, the diagnostic value of these estimations is strictly limited. In acute viral hepatitis, IgM levels rise early in the illness in both endemic and long-incubation types of the disease (Walker, Doniach, Willette, Cameron & Dane 1970) and immunoglobulin measurements therefore cannot be used to differentiate these two conditions. However, emergence and per-
